Evidence map›Paper›PMID 40173049›Full record

ArticleCancer research2025

Spatial Profiling Identifies Regionally Distinct Microenvironments and Targetable Immunosuppressive Mechanisms in Pediatric Osteosarcoma Pulmonary Metastases.

Jason Eigenbrood, Nathan Wong, Paul Mallory, Janice S Pereira, Demond Williams, Douglass W Morris-Ii, Jessica A Beck, James C Cronk, Carly M Sayers, Monica Mendez and 10 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Jason Eigenbrood *Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0009-0002-9117-2782
Nathan Wong *Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-8882-3401
Paul MalloryImaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0003-2266-2577
Janice S PereiraPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0009-0009-7819-4566
Demond WilliamsPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0009-0009-0398-0028
Douglass W Morris-IiPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0009-0004-3984-1963
Jessica A BeckComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-0145-7606
James C CronkPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-6401-0740
Carly M SayersPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-8554-0281
Monica MendezDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0009-0008-4121-4773
Linus KaiserDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0009-0004-7179-081X
Julie GalindoDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0009-0007-9171-7726
Jatinder SinghCenter for Cancer Research Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory, Bethesda, Maryland.ORCID 0009-0006-7152-2131
Ashley CardamoneImaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0009-0000-2470-8335
Milind PoreImaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0001-6513-653X
Michael KellyCenter for Cancer Research Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory, Bethesda, Maryland.ORCID 0000-0003-0654-2778
Amy K LeBlancComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-7656-9859
Jennifer CotterDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0000-0002-1420-3314
Rosandra N KaplanPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-8580-0001
Troy A McEachronPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-0695-5783

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
LAB RESEARCH TRAINING IN PEDIATRIC ONCOLOGY-HEMATOLOGYT32CA060441 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN D FRIEDMAN · 1993 to 2026
$14.9M
Identification of immune evasion mechanisms in the osteosarcoma microenvironmentZIABC012056 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCEACHRON, TROY · 2021 to 2025
$6.4M
Intramural NIH HHS ZIA BC012056National Institutes of Health (NIH) 5P30CA014089-45National Institutes of Health (NIH) ZIABC012056NCI NIH HHS 75N91019D00024NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS T32 CA060441
6 · The paper itself

Abstract

Osteosarcoma is the most common malignant bone tumor in young patients and remains a significant clinical challenge, particularly at the metastatic stage. Studies detailing the immunosuppressive mechanisms within the metastatic osteosarcoma microenvironment are needed to elucidate the cellular communities in the metastatic microenvironment that support metastatic growth and to identify therapeutic approaches to target the cross-talk between cancer cells and their microenvironment. In this study, we performed spatial transcriptional profiling on a cohort of osteosarcoma pulmonary metastases from pediatric patients. The data revealed a conserved spatial gene expression pattern resembling a foreign body granuloma, characterized by peripheral inflammatory signaling, fibrocollagenous encapsulation, lymphocyte exclusion, and peritumoral macrophage accumulation. The intratumoral microenvironment of these lesions, however, lacked inflammatory signaling. Exploration of spatially distinct drug-gene interactions identified the CXCR4 signaling axis, which displayed spatial heterogeneity and complexity, as a potential therapeutic target that bridges both the intra- and extratumoral microenvironments. Collectively, this study reveals that metastatic osteosarcoma comprises multiple regionally distinct immunosuppressive microenvironments. SIGNIFICANCE: Exploration of spatially resolved microenvironments in metastatic osteosarcoma tissues reveals how the tissue architecture promotes immunosuppression and identifies actionable processes to enhance immunotherapy efficacy.

Indexed as

Bone NeoplasmsLung NeoplasmsOsteosarcomaTumor MicroenvironmentAdolescentChildFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleReceptors, CXCR4Signal TransductionCXCR4 protein, humanReceptors, CXCR4

Identifiers

PMID40173049
PMCPMC12170161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.